NK cell–activating receptors in newly diagnosed patients treated with lenalidomide and ultra low dose dexamethasone. NK cell–activating receptors (DNAM-1, 2B4, NKG2D, NKp46, NKp30 an NKp44) were analyzed on CD16⁺CD56⁺ NK cells from 5 newly diagnosed patients on induction therapy (IC) receiving 25 mg/d lenalidomide and 60 mg/cycle of dexamethasone, and 13 newly diagnosed patients on maintenance therapy with lenalidomide only. Data are presented as mean fluorescence intensity (MFI), a significant difference in MFI between groups is represented by * (P = < .05).